Hibsago, GSK's new hepatitis B treatment, recently secured approval from the US FDA, allowing patients to better manage their condition after therapy. This approval is vital as GSK aims for annual revenues of over £40 billion by 2031. The drug is already approved in Japan and is being assessed in China and Europe. Collaboration with Ionis Pharmaceuticals means they will receive milestone payments.